IDH2 and anemia: Among all 239 patients: grade 3/4 AEs: hyperbilirubinemia (12%), IDH‐inhibitor–associated differentiation syndrome (retinoic acid syndrome; 6%), thrombocytopenia (6%), anemia (5%)30‐d and 60‐d mortality: 5.1% and 13.1%